Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and Tissue Array Studies.
To obtain matched tumor tissue samples of trial participants dermatofibrosarcoma protuberans (DFSP)for the purpose of determining whether imatinib mesylate affects autocrine/paracrine stimulated signal transduction through the platelet-derived growth factor receptor pathway in DFSP by comparing the level of phosphorylated platelet-derived growth factor receptor beta (PDGFRB) in DFSP after up to 2 weeks of treatment with imatinib to the level of phosphorylated PDGFRB pre-treatment.
Prior to and after 2-weeks of imatinib therapy
Scott Schuetze, MD, PhD
University of Michigan
United States: Institutional Review Board
|MD Anderson Cancer Center||Houston, Texas 77030-4096|
|University of Michigan Comprehensive Cancer Center||Ann Arbor, Michigan 48109-0752|
|H. Lee Moffitt Cancer Center||Tampa, Florida 33612|
|Pennsylvania Onc/Hem Assoc.||Philadelphia, Pennsylvania 19106|